scholarly journals SAFETY OF SIBLING CORD BLOOD CELL INFUSION FOR CHILDREN WITH CEREBRAL PALSY

2020 ◽  
Vol 56 (S2) ◽  
pp. 24-25
Keyword(s):  
Cerebral Palsy ◽  
Blood Cell ◽  
Cord Blood ◽  
Cord Blood Cell ◽  
Children With Cerebral Palsy

scholarly journals Single group multisite safety trial of sibling cord blood cell infusion to children with cerebral palsy: study protocol and rationale

BMJ Open ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. e034974
Author(s):  
Kylie Crompton ◽  
Iona Novak ◽  
Michael Fahey ◽  
Nadia Badawi ◽  
Euan Wallace ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Blood Cell ◽  
Cord Blood ◽  
Preliminary Evidence ◽  
Fine Motor ◽  
Life Outcomes ◽  
Single Group ◽  
Human Research Ethics ◽  
Cord Blood Cell ◽  
Registration Number

IntroductionCerebral palsy (CP) is the most common physical disability of childhood but has no cure. Stem cells have the potential to improve brain injury and are proposed as a therapy for CP. However, many questions remain unanswered about the most appropriate cell type, timing of infusions, dose required and associated risks. Therefore, human safety and efficacy trials are necessary to progress knowledge in the field.Methods and analysisThis is a single group study with sample size n=12 to investigate safety of single-dose intravenous 12/12 human leucocyte antigen-matched sibling cord blood cell infusion to children with CP aged 1–16 years without immune suppression. The study is similar to a 3+3 design, where the first two groups of participants have severe CP, and the final six participants include children with all motor severities. Children will be monitored for adverse events and the duration that donor cells are detected. Assessments at baseline, 3 and 12 months will investigate safety and preliminary evidence of change in gross motor, fine motor, cognitive and quality of life outcomes.Ethics and disseminationFull approval was obtained from The Royal Children’s Hospital Human Research Ethics Committee, and a clinical trial notification was accepted by Australia’s Therapeutic Goods Administration. Participant guardian informed consent will be obtained before any study procedures. The main results of this study will be submitted for publication in a peer-reviewed journal.Trial registration numberACTRN12616000403437,NCT03087110.

Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy

2015 ◽  
Vol 24 (19) ◽  
pp. 2259-2268 ◽  
Author(s):  
Mino Kang ◽  
Kyunghoon Min ◽  
Joonyoung Jang ◽  
Seung Chan Kim ◽  
Myung Seo Kang ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Cell Therapy ◽  
Immune Responses ◽  
Blood Cell ◽  
Cord Blood ◽  
Cord Blood Cell

Enhancement of Angiogenic Efficacy of Human Cord Blood Cell Transplantation

2006 ◽  
Vol 12 (6) ◽  
pp. 1651-1661 ◽  
Author(s):  
Seung-Woo Cho ◽  
So-Jung Gwak ◽  
Sun-Woong Kang ◽  
Suk Ho Bhang ◽  
Kang Won Song ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Cell Transplantation ◽  
Human Cord Blood ◽  
Cord Blood Cell

scholarly journals Serum Cytokine Profile, Beta-Hexosaminidase A Enzymatic Activity and GM2 Ganglioside Levels in the Plasma of a Tay-Sachs Disease Patient after Cord Blood Cell Transplantation and Curcumin Administration: A Case Report

Life ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1007
Author(s):  
Alisa A. Shaimardanova ◽  
Daria S. Chulpanova ◽  
Valeriya V. Solovyeva ◽  
Ekaterina E. Garanina ◽  
Ilnur I. Salafutdinov ◽  
...  
Keyword(s):  
Blood Cell ◽  
Enzymatic Activity ◽  
Cord Blood ◽  
Cell Transplantation ◽  
Cytokine Profile ◽  
Serum Cytokine ◽  
Α Subunit ◽  
Cord Blood Cell ◽  
Tay Sachs Disease ◽  
Hexosaminidase A

Tay-Sachs disease (TSD) is a progressive neurodegenerative disorder that occurs due to a deficiency of a β hexosaminidase A (HexA) enzyme, resulting in the accumulation of GM2 gangliosides. In this work, we analyzed the effect of umbilical cord blood cell transplantation (UCBCT) and curcumin administration on the course of the disease in a patient with adult TSD. The patient’s serum cytokine profile was determined using multiplex analysis. The level of GM2 gangliosides in plasma was determined using mass spectrometry. The enzymatic activity of HexA in the plasma of the patient was assessed using a fluorescent substrate assay. The HexA α-subunit (HexA) concentration was determined using ELISA. It was shown that both UCBCT and curcumin administration led to a change in the patient’s cytokine profile. The UCBCT resulted in an increase in the concentration of HexA in the patient’s serum and in an improvement in the patient’s neurological status. However, neither UCBCT nor curcumin were able to alter HexA activity and the level of GM2 in patient’s plasma. The data obtained indicate that UCBCT and curcumin administration can alter the immunity of a patient with TSD, reduce the level of inflammatory cytokines and thereby improve the patient’s condition.

Umbilical cord blood cell-derived neurospheres differentiate into Schwann-like cells

Neuroreport ◽  
2009 ◽  
Vol 20 (4) ◽  
pp. 354-359 ◽  
Author(s):  
Hong-Tian Zhang ◽  
Hao-Yu Cheng ◽  
Liang Zhang ◽  
Juan Fan ◽  
Yi-Zhao Chen ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Cord Blood Cell ◽  
Umbilical Cord Blood Cell
Sign in / Sign up

Export Citation Format

Share Document